Supernus Pharmaceuticals reported a 6% revenue increase, reaching $174.2 million, exceeding analyst expectations. The company achieved a significant profit per share, surprising financial skeptics with better-than-anticipated earnings. Future revenue projections are less optimistic, raising concerns among investors about the coming year’s performance.